CD68 and breast cancer: In a second analogous study, of 147 breast cancer-related genes measured by Nanostring in 21 patients, Jeselsohn et al.26 proposed that sequential breast cancer biopsies reveal activation of an immune response, characterised by a panel of 9 immune-related genes, of which CD68 is known to activate tumour-associated macrophages and implicated in increasingly severe prognosis50, as well as being present in the clinically available Oncotype DX® breast cancer assay8.